denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events
The evolution of CAR-T therapies – where do we stand now with this revolutionary treatment approach?
Join our faculty experts for this 1-hour accredited event about the current role of CAR T-cell therapies in management of patients with relapsed/refractory multiple myeloma (RRMM). Dr. Ajai Chari and Dr. Sikander Ailawadhi will discuss and debate practical challenges such as: Is prior treatment sequencing a significant factor in patient response to CAR T-cell therapy? Should all eligible patients with RRMM receive CAR T-cell therapy, or is fitness/frailty a concern? How can we prevent, identify, and manage adverse events? When is treatment discontinuation the best choice? What administration and cost issues need to be considered? And more...
Bring your hard-hitting questions - attendees can challenge the faculty through our interactive Q&A, and the faculty will challenge you back with a series of interactive, case scenarios.